Abstract
1. Genialis Updates ResponderID, Enhancing Data Flywheel for Improved Clinical Biomarker Discovery
Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, today announced an update to its ResponderID platform, including major innovations to its data flywheel that optimizes the inter-operability of datasets for disease modeling. The patent-pending technology helps link Genialis Expressions, the FAIR-inspired data management and bioinformatics processing software suite with ResponderID, and facilitates the broad deployment of biomarker models across different disease indications and gene expression profiling systems.
The ResponderID platform is a technology suite for clinical and translational research, built from years of experience working with partners across the industry and advanced internal R&D. ResponderID defines, models, and validates new biomarkers for drug development and discovery programs. ResponderID can read the status of virtually any NGS-based biomarker, including bespoke and proprietary signatures, from a single assay. The resulting output provides clinical and translational researchers with a comprehensive molecular portrait of their patients, yielding the most informed decision-making possible.
2. Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy
Guardant Health, Inc., a leading precision oncology company, announced today the introduction of GuardantINFINITY™, a next-generation liquid biopsy that provides new, multi-dimensional insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development.
The new GuardantINFINITY assay provides a more comprehensive molecular profile of tumors than earlier assays, giving researchers access to novel genomic and epigenomic insights to provide a simultaneously deeper and more complete understanding of a tumor's biology, its system-wide interactions and the associated immune response in a range of applications— from therapy selection to molecular response and longitudinal monitoring. The assay's extensive methylome panel helps identify the unique, exome-wide methylation pattern that each tumor delivers, providing an important new dimension of research insights that has been largely unexplored in clinical development to date.
3. BD Launches State-of-the-Art Cloud Software Solution to Streamline Flow Cytometry Research
BD, a leading global medical technology company, has launched BD® Research Cloud, a cloud-based software solution designed to streamline the flow cytometry workflow to enable higher quality experiments with faster time to insight for scientists working across a range of disciplines including immunology, virology, oncology and infectious disease monitoring.
Flow cytometry is an essential tool used to analyze single cells based on their characteristics, letting scientists study them in more detail to better understand health and disease. BD® Research Cloud, developed by the BD software engineers who created FlowJo™ Software, bridges and integrates all of the flow cytometry workflow steps, enabling scientists to more easily design reagent panels, connect instruments with data analysis software, store experimental data and procedures, and manage collaboration with colleagues.
Arogyam Launches Comprehensive Oncology Biomarkers Database
Data on biomarkers utilized in clinical development is woefully missing and not readily available. Arogyam has launched a database of biomarkers supporting precision medicine by curating oncology clinical trials tagged with biomarkers, laboriously classifying, and reshaping the data into a structured format. It covers active trials originating from the U.S., grouped by therapy class, calls out biomarkers utilized along with their function, trials that use liquid biopsy, single cell, and tumor microenvironment biomarkers. Stay on top of oncology clinical development by therapy class, indications, new and emerging biomarkers of relevance, impact of biomarkers on trial design and outcomes, and the competitive environment.
Contact us at